Research Context - Read Before Proceeding
All claims in this article reference preclinical (animal) or in vitro research unless explicitly stated otherwise. No compound discussed here is approved for human therapeutic use in South Africa unless specifically noted. Citations are provided for every material claim - see the References section below. This content is for scientific and educational purposes only. It does not constitute medical advice and must not be interpreted as a therapeutic recommendation. 18+ · Research use only.
The Question Nobody Asks Before Starting
Before most researchers begin a new protocol, they spend considerable time on compound selection. Which peptide? Which supplier? Which purity grade? These are important questions. They are not, however, the most important question for determining protocol quality.
The most important question is: when, relative to what biological conditions, is this compound being introduced into the research system?
The compound you choose sets the ceiling on what your research can observe. The timing and conditions under which you introduce it determine how close to that ceiling your actual data lands. Two protocols using identical compounds, identical doses, identical sources, and identical verification documentation can produce dramatically different data - not because the compounds are different, but because the biological state of the research system at the point of introduction is different.
This guide covers the biology of timing that most research protocols overlook.
---
## Half-Life Is Not a Detail
Every compound has a half-life - the time required for its concentration in the research system to fall to 50% of the peak value. Half-life is one of the most important variables in protocol design, and most researchers treat it as background information rather than a core design parameter.
Here is why it matters:
Accumulation. If you administer a compound on a schedule shorter than its half-life, concentrations accumulate. By the third or fourth administration, the circulating concentration is significantly higher than after the first. If your research is designed to study a specific concentration range, and you have not accounted for accumulation, your actual research conditions are different from your design assumptions.
Receptor exposure duration. A compound with a 30-minute half-life produces a fundamentally different receptor exposure pattern than the same compound with a 6-day half-life. This is not a minor pharmacokinetic nuance. It changes which downstream effects you will observe, when you will observe them, and how to interpret the data.
Administration timing relative to biological rhythms. A compound with a 30-minute half-life administered at 10pm will be largely cleared by the time the research system enters deep sleep cycles. The same compound administered at 9pm may peak during a period of high somatostatin activity. The same compound at 2am may peak during naturally elevated GH release. Same compound. Same dose. Completely different biological context.
The practical implication: before designing your administration timing, you need to know the half-life of your compound, understand how it accumulates over repeated administrations, and map that to the biological cycles that are relevant to what you are studying.
---
## The Fasting State: Why It Changes Everything for GH Research
For researchers studying growth hormone secretagogues (CJC-1295, Ipamorelin) or any compound that acts on the GH axis, there is one biological variable that will make or break your data: somatostatin.
Somatostatin is the hypothalamic peptide that suppresses GH release. It is the brake on the GH system, and it rises predictably in response to:
- Carbohydrate and protein ingestion (especially high-glycaemic loads)
The implications for research timing are concrete. If you administer CJC-1295 and Ipamorelin within two hours of a carbohydrate-rich meal, somatostatin tone will be elevated and the GH pulse response will be substantially blunted. You have not learned anything about what these compounds do - you have studied somatostatin's effect on blocking them.
Research protocols for GH-axis compounds consistently document administration in fasted conditions - typically either first thing in the morning before any food intake, or a minimum of two to three hours after the last meal. This is not a safety requirement. It is a data quality requirement. The fasted state provides a low-somatostatin baseline that allows you to observe the compound's primary mechanism rather than its interaction with an active inhibitory signal.
The same logic extends to cortisol. High cortisol elevates somatostatin. Research conducted during periods of high physiological stress or immediately after intense physical exertion may reflect the cortisol-somatostatin interaction rather than the compound under study.
---
## Biological Windows and What They Mean for Protocol Design
Every physiological process in mammals operates on rhythmic cycles - circadian rhythms, ultradian rhythms, and event-driven rhythms tied to activity, feeding, and sleep. Understanding which cycle is relevant to your research objective tells you when the biological system is most responsive to the variable you are introducing.
GH release and sleep architecture. The largest natural GH pulse in adult physiology occurs during the first episode of slow-wave sleep (deep sleep, stages 3 and 4 of the sleep cycle). This typically occurs 60-90 minutes after sleep onset. Research on GH-axis compounds designed to understand pulse amplification should account for when this natural pulse window occurs - either to align with it or, in some research designs, to deliberately study non-sleep-period responses as a comparison.
Tissue repair and physical activity timing. Research on repair-focused compounds in models that involve exercise or physical activity stressors needs to account for the temporal relationship between the stressor and compound administration. The inflammatory phase after tissue damage typically peaks within 24-48 hours and begins resolving by day three to five. Introducing a compound that modulates the inflammatory phase on day four of an acute injury model is studying a different point in the repair cascade than introducing it on day one.
Circadian effects on inflammation. Inflammatory processes have circadian patterns. Pro-inflammatory cytokine levels tend to peak in the early morning hours in many mammalian models. Anti-inflammatory activity varies by time of day. Research studying inflammatory modulation should either control for administration timing across the circadian cycle or specifically investigate time-of-day effects as a variable.
---
## The Reconstitution Window: A Timing Variable Researchers Miss
There is a timing variable that belongs entirely in the practical rather than the biological category, and it affects the validity of every protocol that uses reconstituted peptides. The full chemistry behind this is covered in our peptide storage and cold-chain guide.
Once you reconstitute a lyophilised peptide in bacteriostatic water, you have approximately 28-30 days at 2-8°C before progressive hydrolysis meaningfully reduces the active compound concentration. This is documented chemistry, not a supplier suggestion.
Here is where timing failures happen in practice:
Day 1 of protocol vs day 28. If your research protocol runs for four weeks using the same reconstituted vial, the compound concentration at week four is not the same as at week one. The potency has declined progressively. A protocol designed to study compound effects across a four-week window with a single reconstituted vial is implicitly studying declining concentration over time - which may or may not be a confounding variable depending on your research design.
Multiple vials, different reconstitution dates. If you reconstitute a second vial on day 15 of a 30-day protocol, your data from days 1-15 and days 16-30 was collected with compounds at different points in their post-reconstitution stability curve. This is a controllable variable - document it. Factor it into your analysis.
Research timing relative to CoA date. The CoA documents purity at manufacture. Storage conditions between manufacture and your research session determine how closely your in-use compound matches the CoA. Temperature logs from shipping, storage dates, and number of days since reconstitution all belong in your research records as metadata.
---
## Designing a Protocol Around Timing: A Framework
Before beginning any research protocol, work through these questions in sequence:
What is the half-life of each compound in my protocol? Look up the pharmacokinetic data. Know whether your compound accumulates across administrations and at what point steady-state concentration is reached.
What biological state do I need the research system to be in at the time of compound introduction? Fasted or fed? High or low cortisol? Specific phase of circadian rhythm? Post-exercise or rested? Define this explicitly.
What is the temporal relationship between my experimental stressor and compound administration? If you are studying repair processes, when relative to the damaging event are you administering the compound? The proliferation phase and the remodelling phase require different timing frameworks.
What is the reconstitution age of my compounds? Track the date of reconstitution for every vial. If a protocol spans more than two weeks, consider whether you need a fresh reconstitution at the midpoint.
Can I control the variables I am not studying? Timing variables you do not control become confounders. If your research runs across a period that includes significant variation in sleep, diet, or activity patterns in the model, you are introducing uncontrolled timing variables. Acknowledge them or eliminate them.
---
## The Research Discipline That Separates Signal from Noise
Here is the honest summary: compound selection determines what biology is available to observe. Protocol timing determines whether you actually observe it.
Researchers who understand their compound's half-life, align administration to the relevant biological window, control for the inhibitory signals that block the mechanisms they are studying, and track the post-reconstitution age of their compounds consistently produce cleaner data than those who do not. Not because they have better compounds. Because they have better protocols.
The compound is the variable. The protocol is the methodology. Methodology determines data quality. Data quality determines whether your conclusions mean anything.
---
## Frequently Asked Questions
Q: When is the best time to administer CJC-1295 and Ipamorelin?
Q: How does half-life affect peptide protocol design? A: Half-life determines how long the compound remains active in the research system and whether concentrations accumulate across multiple administrations. CJC-1295 without DAC (30-minute half-life) creates a pulsatile signal; CJC-1295 with DAC (6–8 day half-life) creates near-continuous stimulation. Understanding half-life is essential for designing protocols where you actually control the variable you are studying.
Q: How long is a reconstituted peptide good for in South Africa? A: 28–30 days when stored at 2–8°C in bacteriostatic water. The benzyl alcohol in bacteriostatic water inhibits microbial growth but does not stop hydrolysis (chemical degradation). After 30 days, progressive potency loss means your dosing assumptions no longer correspond to actual compound concentration. In South Africa's warmer climate, maintaining proper refrigerator storage is especially important.
Q: Should BPC-157 be taken with or without food? A: BPC-157 and TB-500 are less sensitive to feeding status than GH-axis compounds, since their mechanisms do not interact with the somatostatin system. That said, consistent timing relative to food across a research protocol reduces one source of variability. Pick a time and stay consistent throughout the protocol.
Q: How do I design a peptide research protocol from scratch? A: Start with single compounds, not stacks. Know your compound's half-life, its relevant biological window, and what biological state the research system should be in at administration. Establish a baseline, introduce the compound with consistent timing, and document everything (lot numbers, reconstitution dates, storage conditions). Add combinations only after single-compound baselines are established.
Q: Why does protocol timing matter more than compound selection? A: Compound selection determines what biological mechanisms are available to observe. Timing determines whether you actually observe them. A GH secretagogue administered during high somatostatin tone produces blunted data that reflects the inhibitory environment, not the compound's action. The protocol is the methodology; methodology determines whether your data is interpretable.
---
## References
1. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 91(3):799–805. PMID: 16352683
18+ only. All compounds sold for research use only. Not for human consumption. Nothing in this guide constitutes medical advice or dosing guidance.